NEW YORK (GenomeWeb News) – Clarient today said that it has licensed from Minerva Biotechnologies exclusive rights to develop and commercialize a test that identifies the MUC1* protein, a biomarker that researchers believe may be associated with the spread of several cancers.
Clarient believes the biomarker could be used for diagnosis, therapy selection, and monitoring of drug effectiveness in solid tumors. Aliso Viejo, Calif.-based Clarient expects a further year of development to thoroughly evaluate the predictive value of measuring MUC1* in a patient's sample.
"Early research has also demonstrated that MUC1* may play a role in developing resistance to cancer drugs, which means if you can block MUC1*, you may be able to overcome resistance to a drug and, once again, offer that therapy," Clarient CEO Ron Andrews said in a statement.
Andrews added that once the firm is done evaluating and validating a test targeting the MUC1* biomarker, it will aim to commercialize the test through its national pathology distribution network.
The firms noted that there currently are no therapies on the market targeting the MUC1* biomarker.
Terms of the alliance were not disclosed.